You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Jenna's experience with Nucala

Listen to Jenna, prescribed Nucala since June 2016, sharing her experience.

Video player requires JavaScript enabled. You can download this video here: http://videos.gskstatic.com/pharma/GSKpro/Cyprus/cyprus-nucala-patient-ambassador-video-pm-cy-mpl-vid-200005.mp4

Severe eosinophilic asthma

hyperlink,10000

 

Severe asthma is a complex heterogeneous disease affecting up to 10% of people with asthma.1 Depending on criteria used, 20% to 79% of patients with severe asthma have been reported as having eosinophilic inflammation 23

30–40% of patients with severe asthma require regular use of OCS 45which can result in serious and often irreversible adverse effects, including bone fractures, cataracts, bruising, muscle weakness, weight gain, cardiovascular complications and infections.678

Who is right for Nucala?

Nucala is indicated as an add-on treatment for adult, adolescent and paediatric patients (aged 6 or above) with severe refractory eosinophilic asthma.9

Nucala eligibility criteria 9

Meet the types of patients who could benefit from Nucala

Click on the patient type you would like to know more about.
Unless otherwise noted, patient images and cases are for illustrative purposes only.

Violet – Exacerbating patient

Violet, age 50, has been living with asthma for the past 15 years.

After experiencing two severe exacerbations last year, Violet has been constantly worried that it might happen again. Her fear has led to her giving up the one activity she loves most, swimming with her friends.

See also:

Judy – OCS-dependent patient

Judy was diagnosed with asthma seven years ago when she was 32.

Judy is concerned about taking OCS long-term. Her confidence took a hit after gaining weight due to the high dose of steroids. She thought she would at least start feeling better, but now her asthma is uncontrolled again. She feels like it has all been for nothing.

See also:

Manda – high-eos patient

Manda was diagnosed with asthma in her mid-20s; she is now 67. She has had three exacerbations in the last year, requiring hospital stays and oral steroids.

Manda has noticed a dramatic worsening of her asthma over the past year or so. She knows how important it is to keep active as she gets older, but since suffering a severe attack while out with friends a few months ago. Manda prefers not to go too far from home.

See also:

Sara – paediatric patient

Sara is 12 and was diagnosed 5 years ago. She had 2 exacerbations in the last year, one of which led to an ED visit.

After these attacks, Sarah missed school and her mother missed work in order to look after her. She hates having asthma attacks and gets very low, especially about missing out on things with her friends.

See also:

BID, twice daily; FEV1, forced expiratory volume in 1 second; OD, once daily; OCS, oral corticosteroid;

Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within first 3 injections. 9

References:

  1. Moore WC, et al. J Allergy Clin Immunol 2007; 119:405-413.
  2. de Carvalho-Pinto RM, et al. Respir Med. 2012;106:47–56
  3. Albers FC, et al. J Asthma. 2018;55:152–160
  4. The ENFUMOSA Study Group. Eur Respir J. 2003;22:470–477;
  5. Heaney LG, et al. Thorax. 2010;65:787–794;
  6. Walsh LJ, et al. Thorax. 2001;56:279–284;
  7. Lefebvre P, et al. J Allergy Clin Immunol. 2015;136:1488–1495;
  8. Sarnes E,et al. Clin Ther. 2011;33:1413–1432.
  9. Nucala SmPC.
  10. Ortega HG et al. Lancet Respir Med 2016; 4:549–556.

Πρόσκληση για αναφορά εικαζόμενων/πιθανολογούμενων ανεπιθύμητων ενεργειών: Παρακαλώ όπως αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες των προϊόντων στην GSK (Cyprus) Ltd Τηλ. 22397000 Email: cy.safety@gsk.com ή στην Επιτροπή Φαρμακοεπαγρύπνησης συμπληρώνοντας την Κίτρινη Κάρτα www.kitrinikarta.gov.cy

Trade marks are owned by or licensed to the GSK group of companies.
© 2020 GSK group of companies or its licensor.

Prescription Only Medicine
Before prescribing please consult the full SPC which you can request from GSK or access on the website of the Pharmaceutical Services of the Ministry of Health http://www.phs.moh.gov.cy/web/guest/drug-search
Retail price: Nucala Powder for solution for injection 100mg/vial €1189.14
Nucala 100mg in pre-filled pen €1116.49